Key Takeaways
- None of the four current US labels lists brain fog or cognitive impairment as an adverse reaction.
- The four labels together list fatigue, dizziness, low blood sugar, and dehydration, which can affect focus.
- No published trial has been identified that tests short-term focus in young healthy adults taking these drugs.
- A 72-week head-to-head trial reported similar rates of fatigue, dizziness, and headache with tirzepatide and semaglutide.
The current US labels for Mounjaro and Ozempic do not list brain fog or cognitive impairment as an adverse reaction. The term comes from patient accounts rather than clinical trials.
Mounjaro contains tirzepatide and Ozempic contains semaglutide. Both are approved in the US for type 2 diabetes. Weight-loss use of either drug is off-label, meaning the FDA has not approved that use. Zepbound also contains tirzepatide and is approved for weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Wegovy contains semaglutide and is approved for weight management, for lowering the risk of major cardiovascular events in adults with cardiovascular disease and obesity or overweight, and, as an injection, for the liver disease MASH in some adults.
None of the four brands is approved to treat attention problems, so their effect on focus is a different question from Adderall for studying.
What "Brain Fog" on a GLP-1 Feels Like
People use "brain fog" to describe trouble concentrating or thinking clearly. The closest adverse reactions on the labels are fatigue, dizziness, and headache, although not every label lists all three.
- In two randomized Zepbound trials of adults with obesity or overweight lasting up to 72 weeks, 5% to 7% of patients had fatigue, compared with 3% on placebo. Dizziness affected 4% to 5% versus 2%.
- In three randomized Wegovy 2.4 mg trials of adults with obesity or overweight lasting up to 68 weeks, 11% of patients had fatigue, compared with 5% on placebo. Dizziness affected 8% versus 4%, and headache affected 14% versus 10%.
Rates from different trials are not comparable across labels.
What Does Research Say About GLP-1s and Memory or Focus?
Two trials in older adults with early Alzheimer's disease and two observational studies in adults with diabetes have not linked GLP-1 drugs to cognitive harm.
The two randomized trials enrolled 3,808 adults aged 55 to 85 with early Alzheimer's disease. Oral semaglutide, up to 14 mg daily, did not slow clinical progression compared with placebo over 104 weeks.
One observational study of US health records from adults with type 2 diabetes associated semaglutide use with a lower 12-month risk of a recorded cognitive deficit than sitagliptin or glipizide.
A second observational study of US veterans with diabetes, including 215,970 who started a GLP-1 drug, associated GLP-1 use with a lower risk of neurocognitive disorders, including Alzheimer's disease and dementia, than usual care. Neither observational study can show cause.
No published trial has been identified that measures short-term attention or concentration in young healthy adults taking tirzepatide or semaglutide.
Why Can Focus Slip on a GLP-1?
It may be harder to concentrate because of reduced calorie intake, low blood sugar, dehydration, or poor sleep.
- Long gaps without food may affect focus. A meta-analysis of 3,484 healthy adults found no meaningful difference in cognition after short fasts and modest reductions after longer fasts and in younger participants.
- Low blood sugar can affect focus, especially in people who also take insulin or a sulfonylurea, a class of diabetes pills. The Medication Guides for all four drugs list confusion or drowsiness, dizziness, and headache among its symptoms. Federal patient guidance also lists tiredness among mild to moderate symptoms.
- Dehydration may affect attention. The labels link fluid loss from nausea, vomiting, or diarrhea to acute kidney injury and advise drinking fluids. A meta-analysis found that water loss above 2% of body mass impaired cognitive performance, particularly attention.
- Short sleep may affect focus. Consensus guidance from sleep-medicine societies recommends seven or more hours per night for adults and links shorter sleep with impaired performance. The four labels do not list insomnia as an adverse reaction.
How Long Does GLP-1 Brain Fog Last?
No published study has been identified that measures how long GLP-1 brain fog lasts.
The labels for all four drugs report nausea, vomiting, and diarrhea mostly during dose escalation, the period when the weekly dose is raised in steps. Each Zepbound dose step lasts at least four weeks. The Mounjaro and Zepbound labels add that these reports decreased over time.
In two Zepbound trials, most patients who stopped because of adverse reactions did so in the first few months because of gastrointestinal reactions. The labels do not describe how long fatigue or dizziness lasts. Any focus problems tied to nausea or fluid loss may therefore be more common around dose increases.
How Can Students Manage Brain Fog Around Exams?
General measures for fluids, food, and sleep may help focus around exams. Things to keep in mind:
- Drink fluids regularly, as the labels advise.
- Avoid long gaps without food before exams.
- Sleep seven or more hours each night.
- Ask the prescriber whether a planned dose increase falls near an exam week. Any change to the schedule is the prescriber's decision.
- Learn the signs of low blood sugar, especially if you also take insulin or a sulfonylurea.
Tirzepatide vs Semaglutide: Is Brain Fog Different?
Tirzepatide and semaglutide have not been shown to differ in brain fog. A head-to-head trial reported similar rates of fatigue, dizziness, and headache but did not measure cognition.
Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors only. The labels do not say whether this difference affects thinking or focus.
The head-to-head trial randomized 751 adults with obesity, or with overweight and a weight-related condition, who did not have diabetes. It was open-label and lasted 72 weeks. Open-label means participants knew which drug they received. Eli Lilly, which makes tirzepatide, funded the trial. It compared the highest tolerated weekly dose of each drug. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.
The trial's posted results list these rates.
| Adverse event | Tirzepatide (n=374) | Semaglutide (n=376) |
|---|---|---|
| Fatigue | 10.4% | 12.2% |
| Dizziness | 6.4% | 4.8% |
| Headache | 7.2% | 7.2% |
| Nausea | 43.6% | 44.4% |
| Vomiting | 15.0% | 21.3% |
The posted results include no statistical test of these differences. On this evidence, neither drug has a proven advantage for focus.
When Should You See a Doctor About Brain Fog?
See a doctor if brain fog persists or comes with any of these signs:
- Signs of low blood sugar, such as confusion, drowsiness, dizziness, shakiness, or sweating.
- Nausea, vomiting, or diarrhea that does not go away, which the labels say to report right away.
- New or worsening depression or suicidal thoughts.
- Noticeable changes in memory.
Sources
- Drug labels: Mounjaro label, 2026; Zepbound label, 2026; Ozempic label, 2026; Wegovy label, 2026
- Cognition research: Cummings et al., Lancet (EVOKE and EVOKE+), 2026; De Giorgi et al., eClinicalMedicine, 2024; Xie et al., Nat Med, 2025
- Proposed explanations: Bamberg and Moreau, Psychol Bull, 2025; NIDDK Low Blood Glucose (Hypoglycemia), 2021; Wittbrodt and Millard-Stafford, Med Sci Sports Exerc, 2018; Watson et al., Sleep (AASM and SRS consensus), 2015
- Tirzepatide vs semaglutide: Aronne et al., N Engl J Med (SURMOUNT-5), 2025; ClinicalTrials.gov NCT05822830 results, 2025
- When to see a doctor: FDA Drug Safety Communication on GLP-1 RAs and Suicidal Behavior, 2026; NIA Memory Problems, Forgetfulness, and Aging, 2023
This article is for general information and is not medical advice.